Experimental drug reverses severe fatty liver disease by repairing the gut

Researchers have found that an experimental drug, DT-109, dramatically reversed severe fatty liver disease in animal models by fixing gut health and blocking toxins from harming the liver. This breakthrough suggests a novel approach to treating metabolic associated steatohepatitis (MASH) and could pave the way for new treatments for other diseases linked to gut health. The implications are huge, potentially offering a new frontier in treating liver diseases by focusing on gut microbiome health.